miRNA screening

California researchers screened some 850 miRNAs to uncover one that inhibits growth in cancer cells with KRAS mutations, which are linked to poor survival.

MiR-371-3p diminished tolerance to targeted cancer treatment in cell lines and mice, while tolerant cells had enhanced levels of genes regulated by miR-371-3p.

Sistemic will provide its SistemRNA suite of drug development tools in order to accelerate Redx's preclinical development pipeline of more than 250 new drug candidates.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.